Meharry Medical College Minority-Based Community Clinical Oncology Program

描述（由申请人提供）：本申请是Meharry医学院（MMC）基于少数民族的社区临床肿瘤学计划（MBCCOP）的第二次更新，为期9-13年。该计划实施的临床研究方案源自NCI批准的CCOP研究基地，包括东部肿瘤协作组（ECOG）、国家外科辅助乳腺项目（NSABP）、妇科肿瘤组（GOG）、德克萨斯大学MD安德森医院（MDA）、美国外科肿瘤组（ACOSOG）和国家癌症研究所的临床试验支持单位（CTSU）。2010年，我们增加了ACOSOG作为研究基地，以容纳加入我们MBCCO的社区外科肿瘤学家。所有这些研究基地试验都是癌症治疗和癌症预防和控制的国家研究。这些试验中的每一项都有与试验的癌症生物学相关的试验特定入选和排除标准。MMC是一所历史悠久的黑人学院和大学（HBCU），自1876年以来一直在服务，其使命是促进种族和少数民族的专业培训。MMC的主要临床护理地点是位于Meharry的纳什维尔总医院（NGH），主要护理服务不足和贫困的患者，少数民族和种族的患病率较高。作为一个以少数民族为基础的CCOP，MMC来自田纳西州戴维森县，一个主要由少数民族组成的地区。在我们的癌症项目中，有色人种患者约占所有血液学/肿瘤学患者的49%。在MMMC MBCCOP的历史上，非裔美国患者占试验累积的55%，这一比例与我们的总体患者人群几乎相同，表明少数群体参与临床试验没有偏倚或困难。因此，MMC MBCCOP已成功进入少数受试者，与他们在我们医学中心的患病率成比例。最近注意到，西班牙裔患者越来越多地在NGH寻求护理，并开始进入临床试验。女性参加所有试验的比例与其疾病患病率成正比，与男性相比，参加乳腺癌和GOG试验的人数要多得多。从历史上看，进入临床试验的患者中有60%是女性，这是基于最活跃的乳腺癌治疗试验的倾斜率。在本申请的报告期内，接受评估的非裔美国人进入NGH临床试验的患病率以及所有研究方案的所有临床试验中女性的百分比与我们的总结趋势相似。除了临床试验工作，MBCCOP还利用其他资金建立了1）少数民族医生的血液学/肿瘤学奖学金机会，以及2）同行评审资助的癌症问题研究工作，包括国家介绍和最近授予的P20项目研究治疗后的“生存率”。

DESCRIPTION (provided by applicant): This application is the second renewal of the Minority-Based Community Clinical Oncology Program (MBCCOP) of Meharry Medical College (MMC) for years 9-13. The program conducts clinical research protocols derived from NCI approved CCOP research bases including the Eastern Cooperative Oncology Group (ECOG), the National Surgical Adjuvant Breast Program (NSABP), the Gynecology Oncology Group (GOG), the University of Texas MD Anderson Hospital (MDA), the American College of Surgery Oncology Group (ACOSOG) and the Clinical Trials Support Unit (CTSU) of the National Cancer Institute. In 2010, we added the ACOSOG as a research base to accommodate a community based surgical oncologist who has joined our MBCCO. All of these research base trials are national studies of cancer treatment and cancer prevention and control. Each of these trials has trial specific inclusion and exclusion criteria that relate to the cancer biology of the trial. MMCis a Historically Black College and University (HBCU) in continuous service since 1876 whose mission is to facilitate the professional training of racial and ethnic minorities. The main clinicl care site of MMC is the Nashville General Hospital at Meharry (NGH) that predominantly cares for underserved and indigent patients with a high prevalence of racial and ethnic minorities. As a minority based CCOP, MMC draws from Davidson County Tennessee, a region that is substantially composed of minorities. In our cancer program, patients of color represent approximately 49% of all hematology/oncology patients presenting for care. Over the history of the MMMC MBCCOP, African- American patients represented 55% of trial accruals, a rate that is virtually identical to our overall patient population and indicates no bias or difficulty enterig minorities onto clinical trials. The MMC MBCCOP therefore has thus been successful to enter minority subjects in proportion to their prevalence in our medical center. It has been recently noted that Hispanic patients are; increasingly seeking care at the NGH and are beginning to be entered onto clinical trials. Women are entered onto all trials in proportion to their disease prevalence with substantially greater numbers entered onto breast cancer and GOG trials compared to men. Historically, 60% of our patients entered onto clinical trials were women which is a skewed rate based on the most active trials treating breast cancer. During the reporting period of this application, the prevalence of African-Americans evaluated entered onto clinical trials at the NGH and the percentage of women on all clinical trials for all research protocols was similar to our summary trends. In addition to the clinical trial efforts, the MBCCOP has leveraged other funds to establish a 1)Hematology/Oncology fellowship opportunity for minority physicians and 2) a peer-reviewed funded research effort in cancer issues of the underserved that includes national presentations and a recently awarded P20 project studying post-treatment "survivorship" of the underserved.